Literature DB >> 11167780

Bone resorption is increased in young adults with thalassaemia major.

E Voskaridou1, M C Kyrtsonis, E Terpos, M Skordili, I Theodoropoulos, A Bergele, E Diamanti, A Kalovidouris, A Loutradi, D Loukopoulos.   

Abstract

Bone disease in patients with thalassaemia major is a multifactorial and still poorly understood process. The present study evaluated 45 thalassaemic patients using dual X-ray absorptiometry at three sites (lumbar spine, head of femur and forearm) to assess bone mineral density, in parallel with a series of biochemical markers to measure bone formation and bone resorption. To identify possible interfering factors, our patients were grouped according to whether or not they needed transfusion therapy; the presence of hypogonadism was also considered. Our results showed that patients on regular transfusions had a markedly low bone mineral density in contrast to those not requiring blood support and that this finding was more pronounced in the hypogonadic group, irrespectively of sex. The decrease of bone mineral density values was more prominent in the forearm, thus making this site particularly interesting for such studies. Bone formation, as evidenced by the levels of serum alkaline phosphatase and osteocalcin, did not appear to be impaired, while bone resorption was grossly increased in all patient groups. The latter process was clearly evident using the recently introduced measurement of the urinary N-terminal peptides of collagen type I, the sensitivity of which has already been established in other groups of osteoporotic patients. Our conclusion is that, in spite of the severe bone destruction that occurs in thalassaemia major, the fact that bone formation remains intact calls for a more intensive treatment comprising hormonal replacement, bisphosphonates and other agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167780     DOI: 10.1046/j.1365-2141.2001.02549.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  25 in total

Review 1.  Endocrine complications of thalassemia.

Authors:  D Tiosano; Z Hochberg
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

2.  Changes in bone microarchitecture and biomechanical properties in the th3 thalassemia mouse are associated with decreased bone turnover and occur during the period of bone accrual.

Authors:  Maria G Vogiatzi; Jaime Tsay; Kostas Verdelis; Stefano Rivella; Robert W Grady; Stephen Doty; Patricia J Giardina; Adele L Boskey
Journal:  Calcif Tissue Int       Date:  2010-05-07       Impact factor: 4.333

3.  Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.

Authors:  A Lasco; N Morabito; A Gaudio; A Crisafulli; A Meo; G Denuzzo; N Frisina
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

4.  Deletion of ferroportin in murine myeloid cells increases iron accumulation and stimulates osteoclastogenesis in vitro and in vivo.

Authors:  Lei Wang; Bin Fang; Toshifumi Fujiwara; Kimberly Krager; Akshita Gorantla; Chaoyuan Li; Jian Q Feng; Michael L Jennings; Jian Zhou; Nukhet Aykin-Burns; Haibo Zhao
Journal:  J Biol Chem       Date:  2018-05-03       Impact factor: 5.157

5.  Prolidase activity and oxidative status in patients with thalassemia major.

Authors:  Alpay Cakmak; Murat Soker; Ahmet Koc; Nurten Aksoy
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

6.  Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America.

Authors:  Maria G Vogiatzi; Eric A Macklin; Felicia L Trachtenberg; Ellen B Fung; Angela M Cheung; Elliott Vichinsky; Nancy Olivieri; Melody Kirby; Janet L Kwiatkowski; Melody Cunningham; Ingrid A Holm; Martin Fleisher; Robert W Grady; Charles M Peterson; Patricia J Giardina
Journal:  Br J Haematol       Date:  2009-07-13       Impact factor: 6.998

7.  Osteoporosis syndrome in thalassaemia major: an overview.

Authors:  Meropi Toumba; Nicos Skordis
Journal:  J Osteoporos       Date:  2010-05-26

8.  The effect of whole body vibration therapy on bone density in patients with thalassemia: a pilot study.

Authors:  Ellen B Fung; Catherine A Gariepy; Aenor J Sawyer; Annie Higa; Elliott P Vichinsky
Journal:  Am J Hematol       Date:  2012-08-07       Impact factor: 10.047

9.  Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Charoula Xirakia; Konstantinos Varvagiannis; Georgios Boutsikas; Antonios Bilalis; Efstathios Kastritis; Athanasios Papatheodorou; Evangelos Terpos
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

Review 10.  Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.

Authors:  A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis
Journal:  Osteoporos Int       Date:  2016-08-08       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.